Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
HCV antibody testing may miss recent infections in gay men living with HIV

Nucleic acid testing should be used to diagnose acute hepatitis C virus (HCV) infections in gay men living with HIV, Dutch research published in the online edition

Published
23 September 2014
By
Michael Carter
Hepatitis C: Sit in of European patients to request access to new medicines, on occasion of the informal meeting of European Health Ministers in Milan

In support of the Call to EU Ministers of Health and CEOs of Abbvie, BMS, Gilead, Janssen and Merck/MSD regarding Universal Access to Curative Hepatitis C Treatment in the EU an beyond (attached), EPAC, Lila and Nadir with the support of the subscribers of the call, organized a “Sit-In” of people living with hepatitis C and their allies on the 22nd of September, at the Mico Conference Center, in Milan, starting at 11:20 am, to advocate for, and demand, a clear political and public health commitment and leadership from the twenty eight member states of the European Union

Published
22 September 2014
From
EATG
The new $84,000 hepatitis C treatment is losing momentum, for now

Data released by CVS Health on Tuesday show that use of Sovaldi has slowed down since May after the drug's record-setting start last December. The slowdown can partly be explained by the health-care industry's anticipation of more hepatitis C treatments soon hitting the market, including another one from Gilead that could gain FDA approval any day now.

Published
22 September 2014
From
Washington Post
STIs and Hep C levels at all-time high in Australia

The Kirby Institute’s Annual Surveillance Report suggests a number of STIs are continuing to increase, with syphilis and gonorrhoea leading the charge. Hepatitis C infections are also a growing health issue with more people now dying from viral hepatitis infection than from HIV when it was in its peak in the 80s and 90s.

Published
22 September 2014
From
Gay News Network
People living with HIV in the US are infrequently screened for HCV

People living with HIV are infrequently screened for hepatitis C virus (HCV) infection, according to US research published in the online edition of Clinical Infectious Diseases.

Published
22 September 2014
By
Michael Carter
Thousands register for new hepatitis C drug in Egypt sold at 99 percent discount

On Thursday, Gamal Esmat, member of the Egyptian National Committee on Viral Hepatitis told Aswat Masriya that around 1,7000 people had registered hours after online registration opened on the Health Ministry’s website.

Published
19 September 2014
From
Egyptian Streets
Community Leaders, HIV Doctors Oppose Hepatitis C Treatment Barriers

A coalition of hepatitis C advocacy organizations and medical providers has issued an open letter to the Secretary of Health and Human Services calling for an end to restrictions on access to hepatitis C treatment by private insurers and public payers seeking to avoid the cost of newly approved direct-acting antivirals. HIV medical providers also called for reducing barriers to treatment, including restrictions on which medical specialists may treat people with hepatitis C.

Published
17 September 2014
From
HIVandhepatitis.com
Gilead’s Proposed Hepatitis C Medicines License: How Badly Will it Miss the Target?

Gilead’s proposed license, and its limitations, is important because Gilead has applied for patents on Sovaldi® and ledipasvir in many countries, although a number of countries in the probable licensed territory are without patents. As a patent holder, Gilead generally has rights to exclude competitors and charge monopoly prices on these life-saving medicines. The anticipated license will set precise terms on which companies can make generic equivalents and where and under what circumstances those generics can be sold. In other words, Gilead sits in the driver’s seat and has enormous power to decide who does and doesn’t get more affordable access to generics of assured quality.

Published
17 September 2014
From
Infojustice
Access to sofosbuvir in middle-income countries

Gilead is excluding 51 middle income countries (MICs) from its license for sofosbuvir, an oral hepatitis C drug. Across these MICs, where nearly 50 million people are infected with hepatitis C virus (HCV), lack of access to generic sofosbuvir will increase the total cost of curing hepatitis C by an estimated $60 billion dollars, according to I-MAK’s analysis.

Published
17 September 2014
From
I-MAK
Study Dampens HOPE of HIV Organ Donations

The HIV Organ Policy Equity (HOPE) Act, which legalizes research into organ tranplants from HIV-positive donors to HIV-positive recipients, is less than a year old, but a new study already suggests the organs may be of poor quality.

Published
17 September 2014
From
Medscape (requires registration)

Filter by country